Preclinical characterization of CS1003, a novel clinical-stage PD-1 monoclonal antibody

被引：0

作者：

Li, Fu ^{[1
]}

Li, Jingrong ^{[1
]}

Yin, Ke ^{[1
]}

Zhang, Juan ^{[1
]}

Li, Zhenhu ^{[1
]}

Lu, Liang ^{[1
]}

Bao, Yuanwu ^{[1
]}

Pu, Dan ^{[1
]}

Qin, Zhen ^{[1
]}

Zheng, Yong ^{[2
]}

Yang, Baotian ^{[2
]}

Li, Jing ^{[2
]}

Wang, Xinzhong Jon ^{[1
]}

机构：

[1] CStone Pharmaceut Co Ltd, Shanghai, Peoples R China

[2] Wuxi Biol Co Ltd, Shanghai, Peoples R China

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.SABCS18-4121

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4121

引用

页数：2

共 50 条

[21] Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation
Mingzhu Wang
Junchao Wang
Rongjuan Wang
Shasha Jiao
Shuang Wang
Jinchao Zhang
Min Zhang
Communications Biology, 2
[22] PD-1/PD-L1 Monoclonal Antibody Development for Canine Cancer Therapy
Choi, Jin Wook
Withers, Sita S.
Sciammas, Roger
Rebhun, Robert B.
McSorley, Stephen J.
JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
[23] Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody
Yao, Yunqi
Yang, Xiaoning
Li, Jing
Guo, Erhong
Wang, Huiyu
Sun, Chunyun
Hong, Zhangyong
Zhang, Xiao
Jia, Jilei
Wang, Rui
Ma, Juan
Dai, Yaqi
Deng, Mingjing
Yu, Chulin
Sun, Lingling
Xie, Liangzhi
PHARMACEUTICALS, 2025, 18 (03)
[24] Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer
Lou, Beilei
Wei, Hua
Yang, Fang
Wang, Shicong
Yang, Baotian
Zheng, Yong
Zhu, Jiman
Yan, Shaoyu
FRONTIERS IN ONCOLOGY, 2021, 11
[25] GNUV201, A NOVEL HUMAN AND MOUSE CROSSREACTIVE PD-1 MONOCLONAL ANTIBODY FOR CANCER IMMUNOTHERAPY
Kim, Haemi
Kim, Kyoung-Jin
Yoon, Myeong Jin
Choih, Jenny
Cho, Eun Ji
Jung, Hak-Jun
Lee, Kwanghyun
Kim, Jayoung
Park, Chae Gyu
Han, Sungho
Bae, Donggoo
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A509 - A509
[26] Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study
Bishnoi, Sarwan
Kotasek, Dusan
Aghmesheh, Morteza
Yau, Thomas
Cosman, Rasha
Prawira, Amy
Moore, Maggie
Chan, Stephen L.
Mant, Andrew
Eek, Richard
Zielinski, Robert
Su, Rila
Pan, Zhaoxuan
Ma, Yiding
Li, Fei
Li, Peiqi
Tse, Archie N.
CANCER, 2024, 130 (11) : 1991 - 2002
[27] Targeted 212Pb therapy in prostate cancer xenograft mouse model using a novel clinical-stage human monoclonal antibody
Li, Jun
Hua, Jun
Su, Yang
Chen, Ping
Bidlingmaier, Scott
Shen, Sui
Gioeli, Daniel
Dreicer, Robert
Liu, Bin
He, Jiang
NUCLEAR MEDICINE AND BIOLOGY, 2022, 108 : S192 - S192
[28] Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
Li, Yiwen
Carpenito, Carmine
Wang, George
Surguladze, David
Forest, Amelie
Malabunga, Maria
Murphy, Mary
Zhang, Yiwei
Sonyi, Andreas
Chin, Darin
Burtrum, Douglas
Inigo, Ivan
Pennello, Anthony
Shen, Leyi
Malherbe, Laurent
Chen, Xinlei
Hall, Gerald
Haidar, Jaafar N.
Ludwig, Dale L.
Novosiadly, Ruslan D.
Kalos, Michael
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[29] Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1
Nemoto, Yuki
Shosu, Kazuha
Okuda, Masaru
Noguchi, Shunsuke
Mizuno, Takuya
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2018, 198 : 19 - 25
[30] Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody
Jie Fu
Fang Wang
Li-hou Dong
Jing Zhang
Cheng-lian Deng
Xue-li Wang
Xin-yao Xie
Jing Zhang
Ruo-xian Deng
Li-bo Zhang
Hai Wu
Hui Feng
Bo Chen
Hai-feng Song
Acta Pharmacologica Sinica, 2017, 38 : 710 - 718

← 1 2 3 4 5 →